We developed a sensitive EGF receptor detection method for frozen tissue sections using biotinylated EGF as the primary reagent. The method was directly compared with an immunohistochemical technique based on an anti-EGF receptor monoclonal antibody (MAb EGFR1) in normal human and rat tissues and in human tumors. The method was more sensitive than a previously published biotinylated EG"Sed technique. In normal human tissues and in 37 of the 50 tumors, the binding pattern mirrored that of positive staining with EGFR1. Five further tumors showed weak immunoreactivity, but in these no binding of biotinylated EGF
Introduction
Epidermal growth factor (EGF) receptors are known to be expressed in many normal tissues and overexpressed in a proportion of human tumors from different origins. It has been suggested that for certain tumor types, the EGF receptor status of individual tumors may affect prognosis (reviewed by Gullick, 1991) . Immunohistochemical methods for detection of EGF receptors are therefore well established, with many anti-EGF receptor antibodies now available. However, controls to confirm fully the specificity of these antibodies for the active receptor rather than a non-functional receptor or an unrelated protein cannot easily be performed. As antibodies raised against human EGF receptors frequently bind with only low affinity to receptors from other species, they are often of limited use for animal studies.
Histochemical methods for detection of EGF receptors that rely on binding of the labeled ligand to tissue sections provide an alternative to antibody-based techniques. Parallel incubations in the presence of an excess of the unlabeled ligand provide a stringent control against nonspecific binding. In addition, only active recep-' Correspondence to: Jonathan Reeves, PhD, University Dept. of Surgcry. Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G312ER. UK. was detected. The remaining eight tumors were negative by both techniques. The discordant cases may reflect a lower level of sensitivity of the ligand-binding technique or, alternatively, abnormal receptors may have been expressed in these tissues. EGF receptors could be detected in rat liver with biotinylated EGF but not with the antibody, indicating the usefulness of the ligand-based technique in cross-species studies. ( J Histochem Cpochcm 42307-314, 1994) KEY WORDS: Epidermal growth factor; Epidermal growth factor receptors; Biotinylated epidermal growth factor; Immunohistochemistry; Histochemistry; Ligand binding. tors capable of binding ligand are detected by such techniques. As mouse EGF binds to receptors from other species with similar affinity, this ligand can be used to detect the receptors in animal and human tissues.
Previous reports have described the use of biotinylated EGF to detect EGF receptors in frozen tissue sections (Torp et al., 1991; Spitzer et al., 1989) . However, in our hands these methods, which involved direct detection of the biotin label with low levels of signal amplification, could detect only the highest levels of EGF receptor expression and were considerably less sensitive than routine immunohistochemical techniques. This article gives a detailed description of a sensitive method for detection of EGF receptors in frozen tissue sections, based on biotinylated EGF as the primary reagent with a multilayer signal amplification system. With a range of normal and tumor tissues, the method is directly compared with an immunohistochemical technique based on a monoclonal antibody (MAb) against the human EGF receptor (EGFR1).
Materials and Methods

Materids
Monoclonal anti-EGF receptor antibody (EGFR1) (Waterfield et al., 1982) was a generous gift from Dr. Peter Goodfellow (Imperial Cancer Research Fund, London) and the IgG2b fraction was purified from ascites fluid by protein A affinity chromatography (Ey et al., 1978) . Non-immune mouse IgG2b was similarly purified from normal mouse serum. Monoclonal antibiotin antibody was donated by Dr. Stuart Marshall-Clarke (Department of Human Anatomy and Cell Biology, University of Liverpool). Biotinconjugated rabbit anti-mouse immunoglobulin was purchased from Dako (High Wycombe, UK) . The streptavidin-biotin-peroxidase complex was prepared and used as for the avidin-biotin-peroxidase complex described by Hsu et al. (1981) . except that N-biotinyl-E-aminocaproic acid N-hydroxysuccinimide ester, incorporating a spacer arm, was used as the biotinylating reagent. Other reagents were purchased from Sigma (Poole, UK).
Preparation of Biotinylated EGF
Mouse EGF was purified by the classical method of Savage and Cohen (1972) and quantified with uv absorbence (Taylor et al., 1974) . Biotin was coupled to mouse EGF via a reactive N-hydroxysuccinimide derivative incorporating a spacer arm to reduce the possibility of steric hindrance during the detection of receptor-bound biotinylated EGF, A 100-fold molar excess of the biotinylating reagent was used to ensure maximal incorporation of biotin. N-Biotinyl-E-aminocaproic acid N-hydroxysuccinimide ester (7.5 mg)
was dissolved in 100 pl of dimethylsulfoxide and added to 1 mg of mouse EGF in 1 ml of 0.1 M NaHC03. (As the preparation of mouse EGF involves lyophilizing the material from an ammonium acetate solution, any contaminating ammonium ions must be removed by dialysis or gel filtration before the biotinylation reaction.) After gentle agitation at 2O' C for 4 hr, the unreacted biotinylating reagent was separated from the labeled protein by gel filtration (Bio-Gel P6; Bio-Rad Laboratories, Hemel Hempstead, UK). Biotinylated EGF was stored in working aliquots at -7O'C, with liale loss of activity over 2 years.
Characterization of Biotinylated EGF
Biotinylated EGF was quantified and the receptor-binding activity was determined in a placental membrane radioreceptor assay using unlabeled EGF as a standard. Mouse EGF was radioiodinated by the chloramine-T method (Hunter and Greenwood, 1962) to a specific activity of 250 pci/pg and human syncytiotrophoblast plasma membranes were prepared by cold isotonic saline extraction (Smith et al., 1974) . The assay was performed in 96-well plates and all reagents were diluted in PBSlBSA [lo mM sodium phosphate, 140 mM sodium chloride, pH 7.4 (PBS) containing 1% bovine serum albumin].
['251]-EGF (25,000 CPM), a range of quantities of unlabeled or biotinylated EGF (100 pg to 10 ng), and 10 pg of placental membranes in a total volume of 300 pl were incubated for 1 hr at 2O' C. The membranes were harvested and washed onto glass fiber filter papers (GFA filter mats) (Whaunan International; Maidstone, UK) in a multiple manifold vacuum cell harvester. The radioactivity bound to the filters was counted in a gamma counter.
The proportion of EGF molecules labeled with biotin was determined by immunoaffinity chromatography. One mg of affinity-purified goat polyclonal anti-biotin antibody (Sigma) was coupled to 250 mg of cyanogen bromide-activated Sepharose 4B (as described in Harlow and Lane, 1988) . The gel was packed into a column to give a total bed volume of 1 ml and equilibrated with 0.1 M Eis-HC1, 0.5 M NaCI. pH 7.5 (sample buffer).
One pg of unlabeled EGF or 1 pg of biotinylated EGF was applied to the column, and after the sample had run into the gel the column was sealed for 30 min. The gel was washed with sample buffer and 1-ml fractions were collected. After the passage of 5 ml, the buffer was changed to 0.1 M sodium acetate, 0.5 M NaCI, pH 2, and further fractions were collected. The EGFbinding activity within the collected fractions was determined in the radioreceptor assay described above.
EGF Receptor Detection in Tissue Sections
The following labeling methods are summarized in Figure 1 . Tissues were frozen and stored in liquid nitrogen immediately on collection. Five-bm cryostat sections were cut and thawed onto 3-aminopropyl triethoxysilanecoated slides and air-dried. Sections were either processed immediately or desiccated and stored at -70°C for later use. All antibodies in the following procedures were diluted in PBS containing 10% normal rabbit serum and 10% normal human serum (or 10% rat serum for rat tissues) and three 5-min washes in PBS were performed between each incubation. The peroxidase signal was developed with a 10-min application of 0.025% diaminobenzidine tetrahydrochloride, 0.07% NiCl2.6H20, and 0.010/0 H202 in PBS (Ni-DAB).
Biotinylated EGF as the Primary Reagent. The slides were immersed in absolute acetone for 10 min, washed in PBS, and endogenous biotin was blocked if necessary (see below). The sections were incubated for 2 hr with 50 ng/ml of biotinylated EGF diluted in PBS/l% BSA with or without a 200-fold excess of the unlabeled growth factor. The sections were given three 2-min washes in PBS before the growth factor was fixed to the receptor with 4% formaldehyde buffered with 100 mM sodium phosphate, pH 7, for 10 min. The slides were then thoroughly washed in PBS (three times for 10 min) before detection of the biotin label by one of the following methods. Figure 1A) . The sections were incubated for 30 min with the streptavidin-biotin-peroxidase complex. The peroxidase label was visualized with Ni-DAB and the slides were dehydrated and mounted. Figure IB) . Nonspecific binding was blocked with a 10-min incubation in 25% normal human serum (or rat scrum for rat tissues) and 25% normal rabbit serum in PBS. The blocker was aspirated from the sections and the monoclonal anti-biotin antibody was applied at 1 pgglml for 60 min. The biotin-conjugated secondary antibody was then applied at a dilution of 1:400 for 30 min. followed by the streptavidin-biotin-peroxidase complex for a further 30 min. The peroxidase label was visualized with Ni-DAB and the slides were dehydrated and mounted.
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Monoclonal Anti-EGF Rereptor Antibody as the Primacy Reagent (Figure IC) . The slides were immersed in absolute acetone at room tcmpcrature for 10 min and washed in PBS. and endogenous biotin was blocked if necessary (sec below). Nonspecific binding was suppressed with 25% normal human serum (or rat scrum for rat tissues) and 2 5 % normal rabbit serum in PBS for 10 min. The serum was aspirated from the sections and EGFRl or non-immune mouse IgGZb was then applied for 60 min at a concentration of 1 pgglml. The biotinylated secondary antibody was then applied at a dilution of 1:400. followed by the streptavidin-biotin-peroxidase complex for 30 min. The peroxidase label was visualized with NI-DAB and the slides were dehydrated and mounted.
Elimination of Nonspecific Binding During Streptavidin-Biotin Histochemistry. The problem of nonspecific binding was present in certain tissues with both the antibody and the biotinylatcd EGF-based method of detecting EGF receptors. The nonspecific binding became more pronounced with an increase in the sensitivity of the biotin detection technique and was most evident with the high-amplification method of detecting biotinylatcd EGF. The problem was the result of the strcptavidin-biotin-pcroxidase complex and the anti-biotin antibody binding to a biotin-like component within the tissue sections ( Figure 2 ). Nonspecific binding due to endogenous biotin in tissue sections has been noted before in immunohistochemical techniques employing avidin-biotin systems (Wood and Warnke. 1981) . especially in liver and kidney. This problem was reduced by adding two simple steps to the above procedures, which enabled a clear detection of biotin labels in tissues. such as liver. with high lcvcls of endogenous biotin (Figures SB, 5C . SE, and 5F). Before treatment of the sections with biotinylated EGF or EGFRl they were incubated with a 50% solution of egg white for 60 min. After washing, the sections were then incubated with a solution of 0.02% biotin in PBS for 30 min. The slides were washed and biotinylated EGF or the antibody was applied as described above.
The egg white solution was prepared by dissolving the white of one hen's egg in an equal volume of PBS and removing the insoluble material by centrifugation. The preparation was stored at -2O'C in working aliquots. Biotin was dissolved in dimethylsulfoxide to give a 1% solution and diluted in PBS accordingly. The rationale behind this blocking procedure is as follows: egg white is a rich source of avidin, a tetravalent biotin-binding protein, which binds to endogenous biotin within the tissue sections. Once bound, this leaves three unoccupied biotin-binding sites per avidin molecule. These are then saturated by the addition of free biotin to prevcnt binding of the biotinylatcd growth factors or antibodies used later in the techniques. This blocking procedure is effective at masking endogenous biotin from both labeled streptavidin complexes and the anti-biotin antibody used in this study.
Analysis of Stained Tissue Sections
Parallel frozen sections of normal human placenta, skin, and liver, and tumors of the breast (n = 14). cervix (n = 16), stomach (n = 12). and bladder (n = 8). and normal rat liver were stained for EGF receptors by the antibody and the sensitive biotinylated EGFbaxd methods. The distribution of stain was compared between the two methods by an independent pathologist (AMM).
Results
Characterization of Biotinylated EGF
Biotinylation of 1 mg of unlabeled EGF gave a product with approximately 800 pg of receptor-binding activity, suggesting little loss of activity due to biotinylation. In addition, the labeled and unlabeled peptides produced superimposable competitive binding curves (Figure 3A) . More than 95% of the functional EGF molecules were labeled with biotin after the biotinylation reaction (Figure 3B) , indicating that no further purification of the labeled preparation was necessary.
Detection of EGF Receptors in Tissue Sections
When the two EGF receptor detection methods based on biotinylated EGF were compared, it was clear that Method B, involv-ing high levels of amplification, was more sensitive. Indeed, receptors in many tissues could be demonstrated with Method B but not with Method A. Only in the most highly expressing tissues, such as placenta, could the receptors be detected with the less sensitive method. The technique involving amplification of the biotin signal was therefore selected as the method of choice for detection of receptor-bound biotinylated EGF in the results presented below.
In human placenta, a tissue with particularly high levels of EGF receptors (Richards et al., 1983) , both the antibody method and the high-amplification ligand-based method of detecting the receptors yielded stains of similar distribution and intensity (Figures 4A  and 4C) . Nonspecific staining where non-immune IgGzb was substituted for EGFRl was minimal (Figure 4B) . Low levels of stain could be seen with the biotinylated EGF control (Figure 4D ), but this could be reduced by increasing the concentration of competing unlabeled EGF. In other tissues the controls for both methods showed only low levels of background staining. However, with intensely staining tissues, as for placenta, it was necessary to use greater than a 200-fold excess of unlabeled EGF to compete totally with the labeled ligand. Human skin stained similarly with antibody and ligand (Figures 5A and 5D) . Although in human liver WIS similv by both techniques (Figures 5B and 5E ).
the intensity ofthe stain produced with biotinylated EGF was lawcr.
No specific stain could be demonstrated with EGFRl in rat liver (Figure 5C) , but biotinylated EGF clearly demonstrated thex rcceptors ( Figure 5F ). In 42 of the 50 tumors the antibody-based technique demonstrated EGF receptors with a range of staining intcn-sities. In 37 ofthex biotinylated EGF indicated an identical pattem of receptor distribution. Tumors that were heavily labeled with the antibody were also heavily labeled with biotinylated EGF. However. the tissues that were labeled moderately with the antibody stained less strongly with the ligand. In five tumors that stained weakly with the antibody, no receptors could be detmed with bi- otinylated EGE There were no cases of positively staining tumors with biotinylated EGF being negative with the antibody. Figure  6 shuws the EGF receptor distribution, as detected by both methods, in representative examples from different types of tumor.
Discussion
This report describes a sensitive histochemical method for detection of EGF receptors in frozen tissue sections, based on biotinylated EGF as the primary reagent. When this method was compared with a highly sensitive antibody-based technique, the receptor distribution was identical in the majority of tissues. The ligand-based technique appeared to be slightly less sensitive than the antibody-based method, because moderately and weakly labeled tissues with the antibody produced weak and negative stains, respectively, with biotinylated EGF. However, we cannot exclude the possibility that the antibody may have been recognizing epitopes distinct from active EGF receptors. Nevertheless, from the results presented here, there is no evidence to suggest that the EGFRl antibody bound to significant numbers of sites other than active EGF receptors or that any of the tumors expressed a class of specific receptor for EGF not recognized by EGFR1. Biotinylated EGF has been used before to detect EGF receptors in frozen tissue sections (Spitzer et al., 1989) . The method described by these authors involved direct application of labeled streptavidin after incubation of the sections with the labeled ligand, resulting in only low levels of signal amplification. When a similar method was used in this study, we could detect EGF receptors only in the highest-expressing tissues, giving a level of sensitivity that was considerably lower than that of routine immunohistochemical methods. Detection of the biotin signal with a multilayered amplification system resulted in a more sensitive technique, allowing visualization of the receptors in tissues with lower levels of expression. A further report describes the detection of EGF receptors in frozen tissue sections from 42 human gliomas with two monoclonal antibodies (including EGFR1) and with biotinylated EGF (Torp et al., 1991) . All the gliomas were reported to express EGF receptors when they were analyzed with biotinylated EGF, but only a proportion of the tissues stained positively with the two antibodies. There was good correlation between the receptor distribution as detected by the two antibodies, but when these ences did not appear to be solely due to variations in the sensitivities of the techniques. Some tissues stained intensely with the antibodies but only weakly with biotinylated EGF, even though the ligand-based method was reported to be more sensitive overall. As gene amplification and rearrangement appear to be frequently associated with EGF receptor overexpression in human gliomas but Gullick, 1991), it is possible that mutations in the receptors from some of the gliomas may have altered the antibody-binding epitopes without &ecting the ligand-binding site. An alternative explanation for the results reported by Torp and co-workers may lie in the methodology. High concentrations of biotinylated EGF were incubated with the tissues sections ( 5 pg/ml), thus making competitive binding controls impossible to perform on a routions of biotinylated EGF may have been interpreted as specific staining in some of the gliomas. For near-maximal saturation of EGF receptors, there should be no need to use concentrations of *e ligand that are more than about five times greater than the dissociation constant ofthe ligand-receptor interaction. Reported d u e s for low affinity EGF receptors arc in the range of3 x 109 M or about 20 ng/ml (Cowley et al., 1986) . Concentrations of biotinylated EGF greater than 100 ng/ml arc therefore unlikely to increase any Spifiic stain but may result in high levels of nonspecific binding.
Other reports describe the use of biotinylated EGF for detection of EGF receptors in routinely processed formalin-fd, paraEiiembedded tissues (Kayser et al., 1990a,b) . The advantages of such a technique are clear. Hawever, we were unable to demonstrate any specific binding of biotinylated or 1251-labeled EGF to routinely processed, paraffin-embedded sections of human placenta (unpublished observations), a tissue especially rich in EGF receptors (Richards et al., 1983) . Biotinylated EGF is therefore a useful tool for the histochemical detection of EGF receptors in frozen tissue sections by the method described here. When the method is compared with a routine technique based on an anti-EGF receptor MAb (EGFRI), there do not appear to be any discrepancies that cannot be explained by slight differences in the sensitivities ofthe techniques. However, this may not be the case for the many other anti-EGF receptor antibodies presently available. The ligand-based histochemical method can therefore serve as an additional control for immunohistochemical techniques to confii that these antibodies recognize receptors that can bind ligand. Although antibodies frequently haw poor interspccies crossreactivity, biotinylated EGF can be used to detect EGF receptors in both human and rat tissues; the method is also likely to be useful for other species. For mouse tissues, howcvcr, a nonmouse anti-biotin antibody w i l l be required to avoid crossreactions ofthe secondary antibody with endogenous immunoglobulins in these tissues.
